Tag: Radiance-HTN

ReCor Medical Announces 6 Month On-Medication Results from RADIANCE-HTN SOLO Clinical Trial and the First Randomization in the RADIANCE-II Pivotal Study

Peripheral/Endo by 0 comments

PALO ALTO, Calif., March 17, 2019 /PRNewswire/ — ReCor Medical, Inc. (“ReCor”) announced the 6 month “on-medication” results from its RADIANCE-HTN SOLO clinical trial with simultaneous publication in Circulation, and the first randomization of patients in its RADIANCE-II pivotal trial of its Paradise® Renal […]

Continue Reading →

ReCor Medical Announces RADIANCE-HTN SOLO Hypertension Study Meets Primary Efficacy Endpoint, Pivotal Study Submission, and New Principal Investigator

Coronary/Structural Heart by 0 comments

ReCor Medical announced today that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients. In addition, the company announced submission of an IDE supplement to the US FDA for a pivotal […]

Continue Reading →